^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GTB-3650

    i
    Other names: GTB-3650, OXS-C3550, Anti-CD16-IL-15-anti-CD33 TriKE
    Associations

    News

    Trials
    Company:
    GT Biopharma
    Drug class:
    NK cell stimulant, IL-15R stimulant, CD33 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
    P1, N=45, Recruiting, Masonic Cancer Center, University of Minnesota | Not yet recruiting --> Recruiting
    Enrollment open • Trispecific
    |
    GTB-3650
    2ms
    HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
    P1, N=45, Not yet recruiting, Masonic Cancer Center, University of Minnesota | Initiation date: Oct 2024 --> Jan 2025
    Trial initiation date • Trispecific
    |
    GTB-3650
    3ms
    HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML (clinicaltrials.gov)
    P1, N=45, Not yet recruiting, Masonic Cancer Center, University of Minnesota
    New P1 trial
    |
    GTB-3650
    2years
    A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML (ASH 2022)
    In the initial study, the iNK cell backbone (iNK cells without the α3 MICA/B CAR) induced potent activity against the AML cell line HL60, and displayed further enhancement of activity with the addition of anti-CD33 TriKE (GTB-3650), representing combined effects of natural cytotoxicity and antibody-dependent cellular cytotoxicity. Studies with primary AML targets, +/- preincubation of decitabine and all-trans retinoic acid, known to upregulate NKG2D ligands in AML, are in progress and will be discussed. In summary, dual-targeting strategies using off-the-shelf CAR NK cells targeting α3 MICA/B in combination with antigen-specific TriKE targeting CD33 represent an ideal clinical strategy to enhance efficacy and durability of treatment in advanced AML.
    Clinical • IO biomarker
    |
    IL15 (Interleukin 15) • NKG2D (killer cell lectin like receptor K1)
    |
    decitabine • GTB-3650